USD 0.0
(0.0%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -250 Thousand USD | 87.97% |
2022 | -2.07 Million USD | -90.04% |
2021 | -1.09 Million USD | 7.13% |
2020 | -1.17 Million USD | 7.39% |
2019 | -1.27 Million USD | -143.21% |
2018 | -523 Thousand USD | 7.92% |
2017 | -568 Thousand USD | 40.21% |
2016 | -950 Thousand USD | -219.78% |
2015 | 793.15 Thousand USD | 136.65% |
2014 | -2.16 Million USD | -28.21% |
2013 | -1.68 Million USD | -20.66% |
2012 | -1.39 Million USD | -7561.33% |
2011 | 18.75 Thousand USD | 0.0% |
2010 | - USD | 0.0% |
2009 | - USD | 100.0% |
2008 | -950.00 USD | 0.0% |
2007 | - USD | 0.0% |
2006 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 FY | -250 Thousand USD | 87.97% |
2023 Q2 | - USD | 100.0% |
2023 Q1 | -245 Thousand USD | 33.6% |
2023 Q3 | - USD | 0.0% |
2023 Q4 | 245 Thousand USD | 0.0% |
2022 Q3 | - USD | 100.0% |
2022 Q1 | - USD | 0.0% |
2022 FY | -2.07 Million USD | -90.04% |
2022 Q4 | -369 Thousand USD | 0.0% |
2022 Q2 | -506 Thousand USD | 0.0% |
2021 Q4 | - USD | 0.0% |
2021 Q3 | - USD | 0.0% |
2021 Q1 | - USD | 0.0% |
2021 Q2 | - USD | 0.0% |
2021 FY | -1.09 Million USD | 7.13% |
2020 Q2 | - USD | 0.0% |
2020 FY | -1.17 Million USD | 7.39% |
2020 Q1 | - USD | -100.0% |
2020 Q3 | - USD | 0.0% |
2020 Q4 | - USD | 0.0% |
2019 Q3 | -72.86 Thousand USD | -3.29% |
2019 FY | -1.27 Million USD | -143.21% |
2019 Q4 | 143.41 Thousand USD | 296.82% |
2019 Q2 | -70.54 Thousand USD | 0.0% |
2019 Q1 | - USD | -100.0% |
2018 Q3 | -99 Thousand USD | 17.5% |
2018 Q4 | 713 Thousand USD | 820.2% |
2018 FY | -523 Thousand USD | 7.92% |
2018 Q1 | -193 Thousand USD | -124.97% |
2018 Q2 | -120 Thousand USD | 37.82% |
2017 Q2 | -216 Thousand USD | 1.37% |
2017 FY | -568 Thousand USD | 40.21% |
2017 Q4 | 773 Thousand USD | 6541.67% |
2017 Q3 | -12 Thousand USD | 94.44% |
2017 Q1 | -219 Thousand USD | -116.29% |
2016 FY | -950 Thousand USD | -219.78% |
2016 Q4 | 1.34 Million USD | 576.6% |
2016 Q2 | -302 Thousand USD | -66.85% |
2016 Q1 | -181 Thousand USD | -180.4% |
2016 Q3 | -282 Thousand USD | 6.62% |
2015 Q4 | 225.11 Thousand USD | -49.98% |
2015 Q2 | 96.55 Thousand USD | 127.08% |
2015 Q1 | -356.57 Thousand USD | 9.17% |
2015 Q3 | 450.06 Thousand USD | 366.14% |
2015 FY | 793.15 Thousand USD | 136.65% |
2014 Q2 | -641.57 Thousand USD | -5232.57% |
2014 Q4 | -392.57 Thousand USD | 26.43% |
2014 Q3 | -533.57 Thousand USD | 16.83% |
2014 FY | -2.16 Million USD | -28.21% |
2014 Q1 | 12.5 Thousand USD | 0.0% |
2013 FY | -1.68 Million USD | -20.66% |
2013 Q2 | 12.5 Thousand USD | 0.0% |
2013 Q3 | 12.5 Thousand USD | 0.0% |
2013 Q4 | 12.5 Thousand USD | 0.0% |
2013 Q1 | 12.5 Thousand USD | 0.0% |
2012 Q4 | 12.5 Thousand USD | 0.0% |
2012 FY | -1.39 Million USD | -7561.33% |
2012 Q3 | 12.5 Thousand USD | 0.0% |
2012 Q2 | 12.5 Thousand USD | 0.0% |
2012 Q1 | 12.5 Thousand USD | 0.0% |
2011 Q4 | 12.5 Thousand USD | 100.0% |
2011 Q1 | - USD | 0.0% |
2011 FY | 18.75 Thousand USD | 0.0% |
2011 Q3 | 6250.00 USD | 0.0% |
2011 Q2 | - USD | 0.0% |
2010 Q1 | - USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2010 Q3 | - USD | 0.0% |
2010 Q4 | - USD | 0.0% |
2010 FY | - USD | 0.0% |
2009 FY | - USD | 100.0% |
2009 Q1 | - USD | 100.0% |
2009 Q4 | - USD | 100.0% |
2009 Q3 | -800.00 USD | -166.67% |
2009 Q2 | -300.00 USD | 0.0% |
2008 Q2 | - USD | 0.0% |
2008 Q3 | - USD | 0.0% |
2008 Q4 | -950.00 USD | 0.0% |
2008 FY | -950.00 USD | 0.0% |
2008 Q1 | - USD | 0.0% |
2007 Q4 | - USD | 0.0% |
2007 Q1 | - USD | 0.0% |
2007 Q2 | - USD | 0.0% |
2007 FY | - USD | 0.0% |
2007 Q3 | - USD | 0.0% |
2006 FY | - USD | 0.0% |
2006 Q4 | - USD | 0.0% |
2006 Q3 | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
AIM ImmunoTech Inc. | 160 Thousand USD | 256.25% |
Armata Pharmaceuticals, Inc. | -29.24 Million USD | 99.145% |
Actinium Pharmaceuticals, Inc. | -709 Thousand USD | 64.739% |
Azitra, Inc. | 260.45 Thousand USD | 195.987% |
Can-Fite BioPharma Ltd. | 743 Thousand USD | 133.647% |
Chromocell Therapeutics Corporation | -2.57 Million USD | 90.308% |
Calidi Biotherapeutics, Inc. | -1.25 Million USD | 80.096% |
CEL-SCI Corporation | -3.95 Million USD | 93.684% |
iBio, Inc. | -1.02 Million USD | 75.61% |
Lineage Cell Therapeutics, Inc. | 8.27 Million USD | 103.022% |
MAIA Biotechnology, Inc. | - USD | Infinity% |
Matinas BioPharma Holdings, Inc. | -13.39 Million USD | 98.133% |
Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -109.565% |
NovaBay Pharmaceuticals, Inc. | 7.89 Million USD | 103.167% |
NanoViricides, Inc. | -759.01 Thousand USD | 67.063% |
Oragenics, Inc. | -15.45 Million USD | 98.382% |
BiomX Inc. | -1.22 Million USD | 79.642% |
BiomX Inc. | -1.22 Million USD | 79.642% |
Protalix BioTherapeutics, Inc. | 42.51 Million USD | 100.588% |
Palatin Technologies, Inc. | 4.39 Million USD | 105.692% |
Scorpius Holdings, Inc. | -2.21 Million USD | 88.721% |